eGFR in changing drug regimens

doi:10.1136/bmj.39247.716806.3A

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Jeffrey K Aronson, reader in clinical pharmacology

Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford OX2 6HA

jeffrey.aronson{at}clinpharm.ox.ac.uk

Giles and Fitzmaurice did not discuss another use of estimated renal function—to guide changes in the dosage regimens of drugs that are eliminated unchanged by the kidneys, that have active metabolites that are eliminated by the kidneys, or whose pharmacodynamic effects are affected by renal insufficiency.1 This is particularly important for drugs that have a low therapeutic index.

Recommendations about drug dosage regimens given in manufacturers' summaries of product characteristics …